APAC Cancer Diagnostics Market Analysis, Companies Profiles, Size, Share, Growth, Trends and Forecast to 2024

APAC cancer diagnostics is expected to reach USD 7.10 billion by 2024 from USD 2.70 billion in 2016, at a CAGR of 12.7% in the forecast period 2017 to 2024.
The major factors driving the growth of market are the technological development, increasing medical tourism in Asia Pacific regions and increasing market reach by Asian countries.
Based on geography, the APAC cancer diagnostics market is segmented into 11 geographical regions, such as,
Japan,
China,
South Korea,
India,
Australia,
Singapore,
Thailand,
Malaysia,
Indonesia,
Philippines and
Rest of APAC.
APAC cancer diagnostics market competition by top players including –
F. Hoffman-La Roche Ltd is going to dominate the cancer diagnostics market, by platform based following with Abbott Laboratories Inc., along with QIAGEN.
The APAC cancer diagnostics market is segmented on the basis of technology, application and geography.
on the basis technology, APAC cancer diagnostics market is segmented into 2 types- platform based and instrument based. In 2017, the cancer diagnostics instrument based segment is expected to dominate the market with a share of 70.2%.
Cancer diagnostics platform based market is segmented into polymerase chain reaction (PCR), in situ hybridization (ISH), immunohistochemistry (IHC), next generation sequencing (NGS), DNA microarrays, flow cytometry and others.
Cancer diagnostics instrument based market is segmented into imaging and biopsy. Imaging is further segmented into magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography- computed tomography (PET-CT), mammography and ultrasound.
On the basis of application, the APAC cancer diagnostics market is segmented into lung cancer, breast cancer, colorectal cancer, melanoma and others.